1,720,968 research outputs found
Temperamento e carattere: profilo nella Bulimia Nervosa e nel Disturbo da Alimentazione incontrollata
No full text
Schizophrenia, drug abuse and violent behaviour: A four-year retrospective research study with inpatients
No full textForma piena e sottosoglia del Disturbo Post-Traumatico da Stress nelle squadre di soccorso sette anni dopo un'alluvione
No full text
Trattamento con escitalopram e peso corporeo, dati preliminari.
No full textIntroduction
Weight gain is a common problem during antidepressant treat- ment, and is also an important factor contributing to noncompli- ance. It is also a key issue influencing obesity-related illnesses. Selective serotonin reuptake inhibitors (SSRIs) seem to differ from each another in terms of their effects on body weight, but the available literature on this topic is sparse, contradictory and lacking of data about new generation SSRIs.
Methods
This work evaluated weight changes during the first three months of escitalopram treatment in 34 outpatients with an ICD- 10 diagnosis of depression with comorbid anxiety, assessed in a naturalistic follow-up. Outcome measures were weight change and clinical improvement assessed with CGI.
Results
After the first three months of therapy, there was a slight de- crease in average body weight compared to baseline. However, the weight loss at three months did not reach statistical signifi- cance. Response to treatment was demonstrated by a statisti- cally significant reduction in CGI score.
Limitations
Both the small sample size and short follow-up times limit our results. Other variables such as depressive severity, atypical features and pre- morbid weight should be taken into account during further follow-up.
Conclusions
Our preliminary data suggest that escitalopram may not be as- sociated with weight gain, and further confirm the efficacy of escitalopram for treatment of depression with comorbid anxiety
Attitude toward prescription and clinical monitoring of lithium salts in a sample of Italian psychiatrists: preliminary data
No full textResults of international prescribing patterns show that lithium prescription and biochemical drug monitoring seem to differ from a country to another. In spite of clear-cut supporting scientific evidence lithium monitoring is often disregarded, incorrectly used or underused. In Italy the trend of lithium prescriptions and biochemical monitoring is far from what suggested in guidelines; even if there's an impressive paucity of data about lithium monitoring and related iatrogenic risks in our country. In order to assess the current attitude in Italy toward lithium treatment in bipolar disorder we asked to a number of senior psychiatrists, working within the national territory, to fill a 34 items interview. Items were grouped in 8 domains, ranging from prescription pattern to therapeutic drug monitoring and other safety measures to prevent iatrogenic harm during lithium therapy. A preliminary analysis of the very first data, collected mainly in Tuscany, suggested that overall knowledge about lithium prescription and biochemical monitoring were good and the few critical topics found in this preliminary study may be addressed with an improvement in information about lithium therapy
The clinical management of aggressive patient in behavioural emergency: some differences between Italy, North America and Former Soviet Union
No full text- …
